Telix Pharmaceuticals (TLX) Limited Receives Transitional Pass-Through payment status for Gozellix

Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 23, Telix Pharmaceuticals Limited (NASDAQ:TLX) announced that the US Centers for Medicare & Medicaid Services had granted Transitional Pass-Through payment status for Gozellix. Gozellix is the company’s next-generation PSMA-PET imaging agent for prostate cancer.

The Transitional Pass-Through payment status means that hospitals will get separate reimbursement for using Gozellix starting October 1, 2025. Gozellix is a kit used to prepare gallium-68 Gozetotide for PET scans that helps detect PSMA-positive lesions in men with prostate cancer, especially those suspected of metastasis or biochemical recurrence.

Moreover, it has also been assigned a permanent HCPCS Level II code A9616, allowing recognition by CMS and commercial insurers for reimbursement starting October 1, 2025.

Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.